Pharmaloz Announced Final Contract Negotiations With Major Lozenge Brand; New Partnership Could Add $35M Annually To Revenue By Late 2025, Bringing Total Revenue To $50M With Projected Net Earnings Of $8M-$10M In 2026; Targets $6M Annual Savings Through Non-Core Operations Cost-Cutting Without Affecting Core Units
The Company will review on Thursday, December 12th, at 12:00 p.m. EST.
GARDEN CITY, NY, Dec. 11, 2024 (GLOBE NEWSWIRE) --ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today provided updates on several key initiatives.
Securing Low-Interest Rate Financing from a Global Private Equity Fund
ProPhase has secured an agreement with a...
Login or create a forever free account to read this news
Sign up/Log in